Keywords
Comprehensive geriatric assessment, Economic evaluation, systematic review
This article is included in the Ageing Populations collection.
Comprehensive Geriatric Assessment (CGA) is a multidimensional interdisciplinary diagnostic process focused on determining an older person's medical, psychological, and functional capabilities to inform a coordinated and integrated health plan. It is a multifactorial intervention requiring longitudinal planning and care coordination, which can utilize variable healthcare resources and have difference health outcomes. This systematic review aims to identify evidence of the cost-effectiveness of CGA in various care settings.
Full economic evaluation studies on CGA will be searched for in the Embase, Medline, CINAHL, CEA registry, and NHSEED databases. Two independent reviewers will screen the studies against the eligibility criteria and extract data using a pretested extraction form. We will include either randomized control trials or model-based economic evaluations, and the outcomes will include the mean costs and effectiveness, incremental cost, and incremental effectiveness. Reporting quality will be assessed using the Consolidated Health Economic Evaluation Reporting Standards (CHEERS-2022) checklist. Narrative summary tables and figures will be used to present the study characteristics.
Ethics approval is not required for this systematic review because we will only utilize publicly available economic evaluation studies rather than individual patient data. The findings of this review will be presented at national and international conferences and published in peer-reviewed journals.
PROSPERO registration no.: CRD42023492586.
Comprehensive geriatric assessment, Economic evaluation, systematic review
With increasing life expectancy and changes in demography1, the demand for healthcare is increasingly rapidly in line with the growth of the older population2. The World Health Organization (WHO) defines "healthy ageing" as "the process of developing and maintaining the functional ability that enables well-being in older age"3, “and research is increasingly focused on identifying to improve that improve healthy ageing. To realize healthy aging, health and social care systems advocate a shift from acute management of cases to efficient configurations of coordinated, longitudinal, and integrated care for older adults4.
Comprehensive Geriatric Assessment (CGA) is a multidimensional interdisciplinary diagnostic process focused on determining an older person's medical, psychological, and functional capabilities to develop a coordinated and integrated care plan5. CGA is often deployed when older people are identified as at risk of "frailty"6. To improve the trajectory of aging, CGA considers various factors, including medical, psychological, and functional impairment, as well as environmental and social issues. CGA requires an interdisciplinary team that may include geriatric specialists, doctors, nurses, and allied health professionals, and aims to produce a coordinated and integrated care plan for treatment, rehabilitation, support, and long-term care.
Over the last decade, CGA is being increasingly used in various health conditions and healthcare settings. For example, reviews have assessed the effectiveness of CGA across various care settings including emergency departments7–9, primary/outpatient care10,11, community settings5,12, hospital inpatient departments13,14, acute geriatric units15,16, and long-term care facilities17. Similarly, the effectiveness of CGA in certain population groups, such as surgical patients18–20, cancer patients21,22, and in the prevention of delirium23, has been reviewed. Although CGA can be provided in multiple settings24 and in multiple populations, this will vary the types and amounts of healthcare resources that are utilized (resulting in variable costs of CGA), and varying levels of intensity may explain the observed heterogeneity in treatment outcomes5.
Although there is strong evidence to support the clinical effectiveness of CGA in managing older adults living with frailty, health systems are increasingly interested in knowing the situations in which CGA can be implemented most efficiently. To examine efficiency, economic evaluation is defined as a comparative analysis of alternative courses of action in terms of both costs and consequences25,26. Economic evaluation can be classified into two categories: partial and full27. Full economic evaluations constitute cost-utility, cost-effectiveness, cost-consequence, cost-minimization, and cost-benefit analyses. Full economic evaluations compare both the costs and effects of alternative comparisons. The cost of the comparators includes the cost of the intervention (the input cost for comparators) and resource-use consequences (health service utilization after the intervention).
Where: Tc: Total cost; Ci: Cost of intervention; Cc: resource use consequence
Effectiveness in the comparison groups can be measured in quality-adjusted life-years (QALYs) or other outcomes such as life-years gained or deaths averted and improvement in frailty.
As the number of economic evaluations of CGA has increased, systematic reviews have contributed to knowledge by systematically identifying the evidence base and providing critical appraisal of reporting quality28,29. Previous systematic reviews exist but offer opportunities for improvement:1) Ellis et al.13 included economic evaluation of CGA in inpatient settings, but primarily to inform a decision analytic model; 2) Briggs et al.5 described the costs of CGA in community settings, but did not critique full economic evaluations; and 3) Garrard et al. mentioned the cost-effectiveness of CGA in primary care, but did not critically appraise reporting quality10. To date, we have not found a systematic review or critical appraisal of the full economic evaluation of CGA. The aim of this protocol is to describe a plan to conduct a systematic review of the economic evaluation of CGA, critically appraise studies reporting quality, describe what data will be extracted, subgroup by various care settings and other characteristics, and explain plans to seek optimal configurations of CGA.
The Preferred Reporting Items for Systematic Reviews and Meta-analyses Protocols 2015 (PRISMA-P) was used to develop the protocol30. The PRISMA-P checklist can be found online (see supplementary Appendix 1)31. This review will be conducted and reported in accordance with the 2020 PRISMA guidelines32.
Inclusion criteria
Types of studies: We will include full economic evaluation studies, either model-based or trial-based, conducted in the English language. Studies with at least six months of follow-up (or time horizon) will be included to appropriately capture the impact on costs and effectiveness5,29.
Population: This review will encompass individuals aged 65 years or older (or 55 years or older if the average age of study participants exceeds 70 years)5. The participants may or may not be acutely unwell, and they should be identified as either frail or at risk of adverse outcomes (e.g., falls, functional decline, nursing home admission).
Intervention: Comprehensive geriatric assessment provided at all levels of care, including home, nursing home, primary care, and tertiary health facilities by a multidisciplinary team for older adults.
Comparison: the comparator is care as usual or standard care
Outcomes: The primary outcomes will include the mean costs, mean effects, incremental costs, and incremental effectiveness.
Setting
All healthcare settings, including CGA provided at home, GP practice, emergency/acute care departments, outpatient departments, inpatient departments, and long-term care facilities, will be considered.
Exclusion criteria
We will exclude studies that do not define population groups as "at risk.” Studies with CGA interventions provided without the explicit involvement of geriatric expertise will not be included. Studies that applied partial economic evaluation will be excluded from the review25,27. Studies with less than six months of follow-up (time horizon) will be excluded. Commentaries, reviews, methodological articles, and editorials will also be excluded. We will exclude studies that are conducted on a single disease condition10.
Using pilot search terms, a preliminary search was conducted on PROSPERO, PubMed, and Embase to identify any similar systematic reviews, either in progress or published, to mitigate the duplication of work. However, no on-going studies identical to the present systematic review were found. Then, a meticulous search strategy was devised with support from a librarian at Trinity College Dublin and the literature5. This strategy was applied across various databases including Embase, MEDLINE, and CINAHL (Supplementary Appendix 2)31. Our approach included a manual search of reference sections in the identified studies and searches for cited references. Additionally, relevant databases specific to economic evaluations, such as the Tufts CEA Registry and NHS Economic Evaluation Database, will be explored. EndNote 21 will be used to import studies, and Covidence will be utilized to manage search results and remove duplicate records.
The study selection will be outlined using a PRISMA flow diagram. Two authors will independently screen the eligible titles and abstracts. The full text of potentially eligible studies will be identified, and a decision to include these full-text articles will be made independently by these two authors. Disagreements to include eligible studies will be approved by discussion in the presence of a third or fourth author (DT or RG). Figure 1 summarizes the flow of the selection process.
Two reviewers independently will extract data from selected studies using a structured data collection form on COVIDENCE after a pilot study. If there are disagreements between the two reviewers, the decision will be made by the third and fourth reviewers.
The Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement provides guidelines for proper reporting of economic evaluations29. This statement includes 28 criteria outlining the minimum standards for such reports. The CHEERS-2022 checklist will be used to evaluate the reporting quality of economic evaluations33.
To enhance the interpretability of the reporting quality of papers, we employed a traffic light color-coding system to visually represent the degree to which the key elements of the CHEERS checklist were addressed:
1. Green: Indicates that all elements were fully addressed.
2. Amber: Indicates that some parts of the elements were only partially addressed.
3. Red: Indicates that the elements were not addressed at all.
4. Black: Indicates that the elements were not applicable.
Figure 2 shows the traffic-light system of the reporting quality of the studies.
In addition, we will assess the risk of bias using ROB-1 for studies that conducted trial-based economic evaluations. Two authors will independently assess the methodological quality, and third and fourth authors will be involved if there is any disagreement between the two reviewers.
A description of the characteristics of the studies and the results will be displayed using a narrative summary and tables. The general characteristics of the included studies will be presented in Table 1.
Narrative reports and tables will be categorized into three sections: intervention characteristics, study characteristics, and study findings. Intervention characteristics encompass the country where the study was conducted, the name of the CGA intervention being investigated, specifics about the services provided to the CGA group, the composition of the team delivering the CGA intervention, details about the target population, and care settings (such as outpatient, inpatient, emergency, and home long-term care facilities). Table 2 shows a description of the characteristics of the interventions being compared.
Study characteristics include the analytical approach (trial-based or model-based), the health economic perspective of the study, the resources used to measure costs, the time horizon, discount rates for both cost and effectiveness, outcomes measured, the instruments used to measure these outcomes, how outcomes are valued, the threshold applied, and the analysis of uncertainty.
Descriptions of resource use (health service utilization) for both groups are presented in Table 3.
A description of the presentation of study characteristics is shown in Table 4.
Study ID | Country of study | Target population | Setting | Analytic approach | Perspective of the study | Time horizon | Outcome | Instrument used to measure outcome | Valuation of outcome |
---|---|---|---|---|---|---|---|---|---|
1 | |||||||||
2 | |||||||||
3 | |||||||||
4 | |||||||||
5 | |||||||||
6 | |||||||||
7 |
The study findings will be presented for each type of measured outcome, including the currency, base year for costs, mean cost and effectiveness of both intervention and control groups, incremental cost, and incremental effectiveness. A description of the results will be presented in Table 5 and Table 6, respectively.
Intervention | Control | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
Study ID | Setting | Perspective | Mean cost | SD of cost | Mean effectiveness | SD of effectiveness | Mean cost | SD of cost | Mean effectiveness | SD of effectiveness |
1 | ||||||||||
2 | ||||||||||
3 | ||||||||||
4 | ||||||||||
5 | ||||||||||
6 |
Author, year | Care Setting | Perspective_ cost | Incremental cost (95% CI) | Effectiveness measure | Incremental effect (95% CI) |
---|---|---|---|---|---|
Study | |||||
Study 2 | |||||
Study 3 | |||||
Study 4 | |||||
Study 5 | |||||
Study 6 |
For cost-utility studies, we will present the difference in costs and quality-adjusted life-years on a cost-effectiveness plane. The cost-effectiveness plane is used to plot the difference in cost and QALY between the intervention and control groups. It is divided into four quadrants: 1) the northeast (NE) quadrant indicates that the intervention is costlier and more effective; 2) the northwest (NW) quadrant indicates higher cost and lower effect; 3) the southwest (SW) quadrant indicates lower cost and lower effect; and 4) the SE quadrant indicates lower cost and lower effect. Figure 3 illustrates the cost-effectiveness plane that will be used to report the incremental costs and QALYs by care setting.
All costs reported in the cost-effectiveness plane will be converted to and the price year of 2024 in Euro using the purchasing power parity and gross domestic product deflator index34. Table 5 and Table 6 present the overall results to be reported in the review.
This review protocol aims to evaluate the cost-effectiveness of CGA. This systematic review will support decision making by assessing and appraising cost-effectiveness across different characteristics, including different care settings and economic perspectives. Our objective is to support policy decision-making by synthesizing and critically appraising existing studies on CGA to inform policy decision-making. Reporting summary findings with attention to intervention characteristics, study characteristics, and results will facilitate a robust interpretation of the findings. For example, the number of health professionals involved and the healthcare setting may influence the cost-effectiveness of interventions, as these factors can impact both cost and effectiveness. Similarly, approaches to the identification, measurement, and valuation of costs and outcomes, as well as the discounting and time horizon of the study, will impact the analysis output. However, some variations could be due to differences in countries' health technology assessment guidelines. For example, the thresholds and discount rates differ from country to country35. Therefore, a complete report that considers the factors affecting cost-effectiveness estimates will support proper interpretation of the results.
Ethics approval is not required for this systematic review, as it solely involves the use of publicly available economic evaluation studies and does not involve individual patient data. Therefore, there are no ethical concerns regarding patient confidentiality or informed consent. The findings of this review will be disseminated through presentations at national and international conferences, to reach a wide audience of researchers and practitioners. Additionally, the results will be published in a peer-reviewed journal to contribute to academic literature and inform future research and policymaking in the field of economic evaluation.
CHEERS, Consolidated Health Economic Evaluation Reporting Standards; CGA, Comprehensive Geriatric Assessment; CPI, Consumer Price Index; DALY, Disability Adjusted Life Year; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life year.
Figshare: Evaluating the Cost-Effectiveness of Comprehensive Geriatric Assessment: Protocol for a Systematic Review of Economic Evaluations, https://doi.org/10.6084/m9.figshare.2823914936
The project contains the following extended data
Data are available under the terms of the Creative Commons Attribution 4.0 International license (CC-BY 4.0).
Figshare: PRISMA -P checklist for ‘Evaluating the Cost-Effectiveness of Comprehensive Geriatric Assessment: Protocol for a Systematic Review of Economic Evaluations’, https://doi.org/10.6084/m9.figshare.2823914936
Data are available under the terms of the Creative Commons Attribution 4.0 International license (CC-BY 4.0).
We express our gratitude to David Mockler, a librarian at Trinity College Dublin, for his support with the initial preparation of search strategies.
Is the rationale for, and objectives of, the study clearly described?
Yes
Is the study design appropriate for the research question?
Yes
Are sufficient details of the methods provided to allow replication by others?
Yes
Are the datasets clearly presented in a useable and accessible format?
Yes
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: Geriatric Medidine
Is the rationale for, and objectives of, the study clearly described?
Yes
Is the study design appropriate for the research question?
Yes
Are sufficient details of the methods provided to allow replication by others?
Partly
Are the datasets clearly presented in a useable and accessible format?
Not applicable
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: Cost-effectiveness, hip fracture, rehabilitiation
Alongside their report, reviewers assign a status to the article:
Invited Reviewers | ||
---|---|---|
1 | 2 | |
Version 1 05 Feb 25 |
read | read |
Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list:
Sign up for content alerts and receive a weekly or monthly email with all newly published articles
Register with HRB Open Research
Already registered? Sign in
Submission to HRB Open Research is open to all HRB grantholders or people working on a HRB-funded/co-funded grant on or since 1 January 2017. Sign up for information about developments, publishing and publications from HRB Open Research.
We'll keep you updated on any major new updates to HRB Open Research
The email address should be the one you originally registered with F1000.
You registered with F1000 via Google, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Google account password, please click here.
You registered with F1000 via Facebook, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Facebook account password, please click here.
If your email address is registered with us, we will email you instructions to reset your password.
If you think you should have received this email but it has not arrived, please check your spam filters and/or contact for further assistance.
Comments on this article Comments (0)